Travere Therapeutics is a San Diego biopharmaceutical company that develops and sells treatments for rare kidney and metabolic diseases. TVTX reports earnings on Mon, Nov 2, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | Guggenheim | Target raised | Buy | |
| Sep 22 | Wedbush | Target raised | Buy | |
| Sep 22 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 10 | Evercore ISI Group | Target raised | Buy | |
| Aug 6 | Canaccord Genuity | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in TVTX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVTX is in one of them and how their past TVTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TVTX in an article yet. Here's the latest on the wider market.
About Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company based in San Diego, California. It develops and sells treatments for people with rare kidney and metabolic diseases. Its approved product, FILSPARI, is indicated to slow kidney function decline in adults with a rare kidney disease called primary IgAN. The company is also seeking approval of FILSPARI for another kidney condition, FSGS, and is developing pegtibatinase for HCU, a genetic metabolic disorder.
- Headquarters
- San Diego, CA